Drugs / Probucol
Probucol
also known as
4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) · Bisbid · DH-581 · Lorelco · Lurselle · NSC-652160 · NSC-86225 · Sinlestal
Small molecule targets ABCA1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | LORELCO | — | 1977-02-01 | fda.gov ↗ |
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01590901 | Feb → Apr 2012 | — | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02707458 | Apr 2016 → Mar 2017 | Alzheimer disease | Douglas Mental Health University Institute | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01726816 | Oct 2012 → Apr 2014 | diabetic kidney disease | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | Missed primary |
| Phase 2 | NCT01142284 | May 2010 → Nov 2012 | peripheral arterial disease | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06225752 | Jun 2024 → Apr 2026 overdue | transient ischemic attack | First Affiliated Hospital of Wannan Medical College | Recruiting | No outcome recorded |
| Phase 49 trials · 1 missed | ||||||
| Phase 4 | NCT03753555 | Dec 2018 → Nov 2027 expected | cerebral atherosclerosis, ischemic stroke | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
| Phase 4 | NCT01031667 | Nov 2009 → Jun 2011 | — | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT02483169 | Jun 2009 → Sep 2016 | brain ischemia, intracerebral hemorrhage | Asan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01013532 | Jun 2009 → Sep 2016 | brain ischemia, intracerebral hemorrhage | Asan Medical Center | Unknown | Mixed |
| Phase 4 | NCT00823875 | Mar → Dec 2009 | cerebral infarction | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00823849 | Oct 2008 → Aug 2009 | arteriosclerosis obliterans, type 2 diabetes mellitus | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00549978 | Oct 2007 → May 2008 | — | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00426348 | May 2007 → Jan 2013 | IgA glomerulonephritis | Guangdong Provincial People's Hospital | Completed | Missed primary |
| Phase 4 | NCT00276133 | Jan 2004 → May 2007 | chronic kidney disease | Yokohama City University Medical Center | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00655330 | May 2008 → May 2017 | diabetic kidney disease, type 2 diabetes mellitus | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06931834 | — | chronic kidney disease, mitochondrial disease | RiboNova Inc. | Available | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 3 | NCT01349010 Comparator | Apr 2011 → Jul 2012 | hyperlipidemia | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02098460 Comparator | Oct 2013 → Mar 2016 | hyperlipidemia | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01291641 Comparator | Mar 2011 → Dec 2016 | hyperlipidemia | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01252056 Comparator | Mar 2010 → Dec 2012 | diabetic kidney disease | Otsuka Beijing Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01000467 Comparator | Feb → Aug 2009 | — | Korea Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Probucol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01013532 ↗ |
| Known as | 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) | “Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol).” PMID 5450842 ↗ Sep 1970 |
| Known as | Bisbid | ChEMBL registry synonym — accepted as the source's own label CHEMBL608 ↗ |
| Known as | DH-581 | ChEMBL registry synonym — accepted as the source's own label CHEMBL608 ↗ |
| Known as | Lorelco | ChEMBL registry synonym — accepted as the source's own label CHEMBL608 ↗ |
| Known as | Lurselle | ChEMBL registry synonym — accepted as the source's own label CHEMBL608 ↗ |
| Known as | NSC-652160 | ChEMBL registry synonym — accepted as the source's own label CHEMBL608 ↗ |
| Known as | NSC-86225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL608 ↗ |
| Known as | Sinlestal | ChEMBL registry synonym — accepted as the source's own label CHEMBL608 ↗ |
| Action | Inhibit | “ATP-binding cassette sub-family A member 1 inhibitor” CHEMBL608 ↗ |
| Modality | Small molecule | — CHEMBL608 ↗ |
| Route | Oral | “250 mg Bid, PO after breakfast and dinner” NCT00823849 ↗ |
| Target | ABCA1 | “ATP-binding cassette sub-family A member 1 inhibitor” CHEMBL608 ↗ |